RS62237B1 - Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih malignih tumora - Google Patents

Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih malignih tumora

Info

Publication number
RS62237B1
RS62237B1 RS20211033A RSP20211033A RS62237B1 RS 62237 B1 RS62237 B1 RS 62237B1 RS 20211033 A RS20211033 A RS 20211033A RS P20211033 A RSP20211033 A RS P20211033A RS 62237 B1 RS62237 B1 RS 62237B1
Authority
RS
Serbia
Prior art keywords
peptides
hcc
cancers
combination
hepatocellular carcinoma
Prior art date
Application number
RS20211033A
Other languages
English (en)
Inventor
Toni Weinschenk
Andrea Mahr
Jens Fritsche
Phillip Müller
Anita Wiebe
Sarah Missel
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52630910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS62237(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of RS62237B1 publication Critical patent/RS62237B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
RS20211033A 2014-12-23 2015-12-16 Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih malignih tumora RS62237B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462096165P 2014-12-23 2014-12-23
GB201423016 2014-12-23
GBGB1501017.6A GB201501017D0 (en) 2014-12-23 2015-01-21 Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
EP19170191.1A EP3545965B1 (en) 2014-12-23 2015-12-16 Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

Publications (1)

Publication Number Publication Date
RS62237B1 true RS62237B1 (sr) 2021-09-30

Family

ID=52630910

Family Applications (4)

Application Number Title Priority Date Filing Date
RS20191606A RS59836B2 (sr) 2014-12-23 2015-12-16 Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih malignih tumora
RS20211276A RS62448B1 (sr) 2014-12-23 2015-12-16 Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih malignih tumora
RS20211033A RS62237B1 (sr) 2014-12-23 2015-12-16 Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih malignih tumora
RS20211341A RS62508B1 (sr) 2014-12-23 2015-12-16 Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih malignih tumora

Family Applications Before (2)

Application Number Title Priority Date Filing Date
RS20191606A RS59836B2 (sr) 2014-12-23 2015-12-16 Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih malignih tumora
RS20211276A RS62448B1 (sr) 2014-12-23 2015-12-16 Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih malignih tumora

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20211341A RS62508B1 (sr) 2014-12-23 2015-12-16 Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih malignih tumora

Country Status (25)

Country Link
US (8) US10064926B2 (sr)
EP (8) EP3715357A1 (sr)
JP (2) JP6906156B2 (sr)
KR (1) KR102284493B1 (sr)
CN (4) CN112538109A (sr)
AR (2) AR103220A1 (sr)
AU (3) AU2015371490B2 (sr)
BR (1) BR112017008972A2 (sr)
CA (1) CA2972126A1 (sr)
CL (1) CL2017001391A1 (sr)
CR (1) CR20170282A (sr)
DK (4) DK3616706T3 (sr)
EA (2) EA201791150A1 (sr)
GB (1) GB201501017D0 (sr)
IL (1) IL250989B (sr)
MA (3) MA40136A1 (sr)
MX (1) MX2017008329A (sr)
PE (1) PE20170940A1 (sr)
PH (1) PH12017500484A1 (sr)
PL (1) PL3236985T5 (sr)
RS (4) RS59836B2 (sr)
SG (1) SG11201703322UA (sr)
SI (3) SI3626729T1 (sr)
TW (1) TWI687436B (sr)
WO (1) WO2016102272A1 (sr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
EP3134114A4 (en) * 2014-04-24 2018-03-14 Rhode Island Hospital Aspartate-beta -hydroxylase induces epitope-specific t cell responses in tumors
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
SG11201703880VA (en) 2014-12-23 2017-07-28 Novartis Ag Triazolopyrimidine compounds and uses thereof
MA48487B1 (fr) 2014-12-23 2021-11-30 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11420136B2 (en) 2016-10-19 2022-08-23 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
IL259931B2 (en) 2015-12-16 2024-02-01 Gritstone Bio Inc Identification of neo-antigens, preparation, and use
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
CA3027246A1 (en) 2016-06-20 2017-12-28 Novartis Ag Crystalline forms of triazolopyrimidine compound
WO2017221092A1 (en) 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
CN109790166A (zh) 2016-06-20 2019-05-21 诺华股份有限公司 咪唑并吡啶化合物用于治疗癌症
IL265805B1 (en) * 2016-10-07 2024-04-01 Io Biotech Aps Arginase immunogenic peptides
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP3573647B1 (en) * 2017-01-27 2023-04-05 Immatics Biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CN111164103A (zh) * 2017-06-14 2020-05-15 西奈山伊坎医学院 检测和治疗对免疫疗法应答的肝细胞癌类别的方法
HRP20211744T1 (hr) 2017-07-14 2022-02-04 Immatics Biotechnologies Gmbh Poboljšana molekula polipeptida dvostruke specifičnosti
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
WO2019030311A1 (en) * 2017-08-09 2019-02-14 Pamgene Bv METHOD OF PREDICTING THE RESPONSE OF PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA TO A MEDICINAL PRODUCT
GB201713700D0 (en) * 2017-08-25 2017-10-11 Anastasis Biotec Ltd Peptide conjugates
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
KR20200090855A (ko) 2017-11-22 2020-07-29 그릿스톤 온콜로지, 인코포레이티드 신생항원에 대한 접합 에피토프 제시 감소
BR112020009889A2 (pt) 2017-12-14 2020-11-03 Flodesign Sonics, Inc. acionador e controlador de transdutor acústico
US20210213058A1 (en) * 2018-03-12 2021-07-15 The Children's Hospital Of Philadelphia Methods and compositions for use of tumor self-antigens in adoptive immunotherapy
DE102018122546B3 (de) * 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
AU2019367647A1 (en) * 2018-10-26 2021-06-03 Ethadox Ltd. Compositions and methods for biodegrading alcohol
CN109663128A (zh) * 2018-11-21 2019-04-23 中国农业大学 一种肺动脉高压标志物及其作为治疗靶点的应用
CA3123006A1 (en) * 2018-12-13 2020-06-18 Rhode Island Hospital Inhibition of asph expressing tumor growth and progression
EP3721899A1 (en) 2019-04-08 2020-10-14 China Medical University Combination therapies comprising dendritic cells-based vaccine and immune checkpoint inhibitor
CN110850086B (zh) * 2019-11-18 2023-05-02 西安交通大学 一种肝移植术后缺血性胆道病变血清诊断标志物acly的应用
CN114315964B (zh) * 2020-03-18 2023-06-13 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原组合、输卵管癌靶标抗原刺激培养的ctl细胞及其应用
EP4130747A1 (en) * 2020-03-30 2023-02-08 Rophelbio Co., Ltd.a Biomarker for cancer immunotherapy and use thereof
EP4153633A1 (en) 2020-05-19 2023-03-29 Amgen Inc. Mageb2 binding constructs
CN112063718A (zh) * 2020-09-18 2020-12-11 中国医科大学 Usp14在肝细胞肝癌诊断、预后判断以及治疗中的应用
CN112043722B (zh) * 2020-09-25 2022-02-15 中国医科大学 Prpf6在前列腺癌及去势抵抗前列腺癌治疗中的应用
CN114574486B (zh) * 2020-12-01 2024-04-16 中国科学院大连化学物理研究所 作用于OPLAH的siRNA、DNA及构建物和应用
WO2022212831A1 (en) 2021-04-02 2022-10-06 Amgen Inc. Mageb2 binding constructs
CA3226568A1 (en) * 2021-07-19 2023-01-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Mct11 antibodies to treat t cell functional exhaustion and enhance cancer immunotherapy
CN113502300B (zh) * 2021-07-21 2024-02-06 徐州医科大学 一种含有hdac10基因启动子序列和报告基因的重组质粒、制备方法及应用
CN115572764A (zh) * 2022-03-30 2023-01-06 江苏鹍远生物技术有限公司 一组肿瘤检测标志物及其用途

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
ES8105035A1 (es) 1978-12-22 1981-05-16 Biogen Nv Un metodo para producir al menos un polipeptido que muestra antigenicidad de hbv
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
ES2138662T3 (es) 1993-06-03 2000-01-16 Therapeutic Antibodies Inc Produccion de fragmentos de anticuerpos.
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
DE69723230T2 (de) 1996-01-17 2004-05-27 Imperial College Innovations Ltd. Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO2001044279A2 (en) * 1999-12-17 2001-06-21 Chiron Corporation Mammalian dishevelled-associated proteins
WO2001062908A2 (en) 2000-02-22 2001-08-30 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
WO2001093913A2 (en) 2000-06-05 2001-12-13 Sunol Molecular Corporation T cell receptor fusions and conjugates and methods of use thereof
WO2002007783A2 (en) 2000-07-20 2002-01-31 Regents Of The University Of Minnesota Radiolabeled immunotoxins
US20050053918A1 (en) 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
JP2005533486A (ja) 2002-02-20 2005-11-10 ダイアックス、コープ Ｍｈｃ−ペプチド複合体結合リガンド
US7311914B2 (en) 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
JP4406607B2 (ja) * 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
ATE432290T1 (de) 2002-11-09 2009-06-15 Immunocore Ltd T ZELL REZEPTOR ßDISPLAYß
US20040096982A1 (en) 2002-11-19 2004-05-20 International Business Machines Corporation Methods and apparatus for analysis of mass spectra
EP1998177A3 (en) * 2003-01-06 2009-02-18 Wyeth Compositions and methods for diagnosing and treating colon cancers
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090075304A1 (en) 2004-05-27 2009-03-19 Weidanz Jon A Methods of assaying vaccine potency
US20090233318A1 (en) 2004-12-28 2009-09-17 Weidanz Jon A Methods of assaying vaccine potency
PL1760089T3 (pl) 2005-09-05 2010-03-31 Immatics Biotechnologies Gmbh Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa
PT1806359E (pt) 2005-09-05 2010-05-25 Immatics Biotechnologies Gmbh Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
PT2183361E (pt) * 2007-07-27 2015-09-11 Immatics Biotechnologies Gmbh Nova imunoterapia para tumores neuronais e cerebrais
US7994276B2 (en) * 2007-07-27 2011-08-09 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
WO2009026547A1 (en) 2007-08-22 2009-02-26 Receptor Logi, Ltd. Methods of assaying vaccine potency
PL2201100T3 (pl) * 2007-09-14 2016-10-31 Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniu
WO2009108372A2 (en) * 2008-02-27 2009-09-03 Receptor Logic, Inc. Antibodies as t cell receptor mimics, methods of production and uses thereof
PL2105501T3 (pl) * 2008-03-27 2016-03-31 Immatics Biotechnologies Gmbh Innowacyjna immunoterapia przeciwko nowotworom neuronów i mózgu
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
WO2009151487A1 (en) * 2008-06-13 2009-12-17 Receptor Logic, Inc. Methods of assaying vaccine potency
DE102008049136B4 (de) 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
US9125850B2 (en) 2009-11-14 2015-09-08 Cardio Vax, Llc Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
BR112013010213A2 (pt) 2010-10-26 2019-09-24 Technion Research & Development Foundation Ltd anticorpos que unem ligantes solúveis de receptores de célula t
RU2013126626A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения гипертензий
RU2013126628A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения аневризм
US20130302362A1 (en) 2010-11-12 2013-11-14 Cedars-Sinai Medical Center Immunomodulatory Compositions, Methods and Systems Comprising Immunogenic Fragments of ApoB-100
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
WO2013070603A1 (en) * 2011-11-11 2013-05-16 Cedars-Sinai Medical Center Compositions and methods for treatment of kidney diseases
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
EP4088737A3 (en) * 2012-09-05 2023-02-08 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
ES2603589T3 (es) 2012-11-08 2017-02-28 F. Hoffmann-La Roche Ag Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
US9134326B2 (en) * 2013-03-14 2015-09-15 Battelle Memorial Institute Biomarkers for liver fibrosis
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
CN103739667B (zh) * 2013-09-24 2017-08-25 上海宇研生物技术有限公司 卵巢癌特异的肿瘤抗原肽及其制备方法
WO2015136072A1 (en) 2014-03-14 2015-09-17 Immunocore Limited Tcr libraries
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
US20180179283A1 (en) 2015-06-08 2018-06-28 Adicet Bio Inc. T cell receptor like antibodies having fine specificity
CA3020530A1 (en) 2016-04-08 2017-10-12 Adaptimmune Limited T cell receptors
MX2018012268A (es) 2016-04-08 2019-02-07 Adaptimmune Ltd Receptores de celulas t.
PL3440106T3 (pl) 2016-04-08 2022-01-31 Adaptimmune Limited Receptory występujące na limfocytach t
RU2735726C2 (ru) 2016-07-27 2020-11-06 Шарп Кабусики Кайся Способы и устройство беспроводной связи с использованием тега значения системной информации
US20200325244A1 (en) 2020-05-18 2020-10-15 Abexxa Biologics, Inc. Antibodies and methods of use thereof
CN110809580A (zh) 2017-01-24 2020-02-18 安贝科思生物制剂公司 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物
BR112019025667A2 (pt) 2017-06-05 2020-09-01 Mie University proteína de ligação ao antígeno que reconhece o peptídeo derivado de mage-a4
CN111328287A (zh) 2017-07-04 2020-06-23 库瑞瓦格股份公司 新型核酸分子
AU2018318303A1 (en) 2017-08-18 2020-04-09 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens
WO2019051001A1 (en) 2017-09-06 2019-03-14 California Institute Of Technology SIGNALING AND BIFUNCTIONAL RECEPTORS HAVING ANTIGENS (SABR)
US20210061914A1 (en) 2017-12-28 2021-03-04 Gritstone Oncology, Inc. Antigen-Binding Proteins Targeting Shared Antigens
US20210363215A1 (en) 2018-04-19 2021-11-25 Board Of Regents, The University Of Texas System T cell receptors with mage-b2 specificity and uses thereof
JP2021525076A (ja) 2018-05-23 2021-09-24 グリットストーン バイオ インコーポレイテッド 共有抗原
US20200291127A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US20200291128A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof
US20200291116A1 (en) 2020-05-18 2020-09-17 Abexxa Biologics, Inc. Antibodies and methods of use thereof

Also Published As

Publication number Publication date
RS59836B1 (sr) 2020-02-28
EP3545965A3 (en) 2019-12-25
EP3626729B1 (en) 2021-09-08
EP3616706A1 (en) 2020-03-04
IL250989A0 (en) 2017-04-30
EP3616706B1 (en) 2021-10-13
JP2021104033A (ja) 2021-07-26
IL250989B (en) 2021-04-29
EA202190587A3 (ru) 2021-09-30
SI3236985T2 (sl) 2023-01-31
WO2016102272A1 (en) 2016-06-30
MA49158A (fr) 2020-03-25
DK3626729T3 (da) 2021-11-01
AU2020213295A1 (en) 2020-09-03
EP3626729A1 (en) 2020-03-25
EP3620168A1 (en) 2020-03-11
US20200376103A1 (en) 2020-12-03
EP3715357A1 (en) 2020-09-30
AR103220A1 (es) 2017-04-26
SI3626729T1 (sl) 2021-11-30
US11786583B2 (en) 2023-10-17
RS59836B2 (sr) 2023-01-31
CN107001414A (zh) 2017-08-01
DK3616706T3 (da) 2021-11-15
CN112646021A (zh) 2021-04-13
RS62448B1 (sr) 2021-11-30
EP3545965B1 (en) 2021-07-21
EP3545965A2 (en) 2019-10-02
PL3236985T4 (pl) 2020-12-14
US20170080070A1 (en) 2017-03-23
PL3236985T5 (pl) 2023-03-06
EP3626731B1 (en) 2021-09-08
MX2017008329A (es) 2017-10-26
US20160250307A1 (en) 2016-09-01
DK3545965T3 (da) 2021-09-13
CN112538109A (zh) 2021-03-23
AU2020213294A1 (en) 2020-09-03
MA40136A1 (fr) 2018-05-31
AU2020213295B2 (en) 2022-09-01
JP6906156B2 (ja) 2021-07-21
CN112646025A (zh) 2021-04-13
SI3236985T1 (sl) 2020-01-31
EP3236985B1 (en) 2019-09-25
EA201791150A1 (ru) 2018-03-30
AU2015371490A1 (en) 2017-03-23
US20190000947A1 (en) 2019-01-03
RS62508B1 (sr) 2021-11-30
EP3626730A1 (en) 2020-03-25
AU2015371490B2 (en) 2020-08-13
KR102284493B1 (ko) 2021-08-02
SG11201703322UA (en) 2017-07-28
AR122964A2 (es) 2022-10-19
US20210268089A1 (en) 2021-09-02
US11406693B2 (en) 2022-08-09
CA2972126A1 (en) 2016-06-30
AU2020213294B2 (en) 2022-10-06
KR20170090447A (ko) 2017-08-07
SI3545965T1 (sl) 2021-11-30
JP2018509135A (ja) 2018-04-05
MA49158B1 (fr) 2021-12-31
US10064926B2 (en) 2018-09-04
MA41237A (fr) 2017-11-01
EA202190587A2 (ru) 2021-06-30
EP3236985A1 (en) 2017-11-01
DK3626731T3 (da) 2021-11-22
PH12017500484A1 (en) 2017-08-07
TW201629096A (zh) 2016-08-16
CL2017001391A1 (es) 2017-12-29
EP3626731A1 (en) 2020-03-25
US20180207252A1 (en) 2018-07-26
BR112017008972A2 (pt) 2018-01-16
GB201501017D0 (en) 2015-03-04
PL3236985T3 (pl) 2020-04-30
TWI687436B (zh) 2020-03-11
EP3236985B2 (en) 2022-09-07
US20200405831A1 (en) 2020-12-31
MA41237B1 (fr) 2019-12-31
PE20170940A1 (es) 2017-07-13
CR20170282A (es) 2018-01-29
US20180207253A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
IL250989A0 (en) New peptides and a combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other types of cancer
SG10202101368WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
GB201505305D0 (en) Novel Peptides and combination of peptides for use in immunotherapy against various tumors
HK1246181A1 (zh) 用於各種腫瘤免疫治療的新型肽和肽組合物
HK1255541A1 (zh) 用於多種癌症免疫治療的新型肽和肽組合物
IL281752A (en) New peptides and combinations of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers